京新药业(002020) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥893,372,399.42, representing a 38.81% increase compared to ¥643,598,548.68 in the same period last year[8] - Net profit attributable to shareholders was ¥131,379,249.16, up 49.25% from ¥88,025,890.09 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥94,231,955.93, reflecting a 20.43% increase from ¥78,248,681.20 in the previous year[8] - Basic earnings per share rose to ¥0.1895, a 58.44% increase from ¥0.1196 in the previous year[8] - Operating revenue grew by 38.81% to ¥893,372,399.42, attributed to an increase in main business income[26] - Operating profit rose by 51.58% to ¥153,925,261.90, driven by increased operating revenue and investment income[30] - Net profit for Q1 2019 was ¥131,530,009.98, representing a 52.3% increase compared to ¥86,374,600.57 in Q1 2018[65] - The total profit for the period was ¥158,012,952.26, up 53.4% from ¥103,050,865.10 in Q1 2018[65] Cash Flow - The net cash flow from operating activities was ¥69,232,593.75, an increase of 38.16% compared to ¥50,109,446.25 in the same period last year[8] - Cash inflow from operating activities reached CNY 1,012,255,923.29, an increase of 30.3% compared to CNY 776,385,856.96 in the previous period[74] - Cash inflow from sales of goods and services was CNY 940,219,381.99, up from CNY 716,370,627.79 in the previous period, reflecting a growth of 31.3%[74] - Cash outflow for purchasing goods and services was CNY 399,430,662.60, an increase of 18.4% from CNY 337,461,427.94 in the previous period[78] - The company reported a net cash increase of -CNY 38,695,110.14, compared to an increase of CNY 45,995,303.07 in the previous period[79] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,246,389,385.99, a 5.10% increase from ¥4,991,769,097.50 at the end of the previous year[8] - Current liabilities totaled CNY 1,574,747,620.55, an increase of 17.4% from CNY 1,341,005,665.56 in the previous period[49] - Total liabilities reached CNY 1,650,998,882.87, up 16.4% from CNY 1,418,374,285.05[51] - Total equity attributable to shareholders was CNY 3,583,362,953.31, an increase of 0.6% from CNY 3,561,772,412.70[51] - Total assets as of March 31, 2019, amounted to ¥5,246,389,385.99, an increase from ¥4,991,769,097.50 at the end of 2018[44] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,988[12] - The largest shareholder, Lü Gang, holds 20.55% of the shares, with a total of 148,997,296 shares[12] Investment and Income - The company reported non-operating income of ¥8,006,000.72 from government subsidies and ¥36,095,859.42 from entrusted investment management[8] - Investment income surged by 323.38% to ¥36,095,859.42, mainly from gains on the disposal of securities[29] - Other income increased significantly to ¥5,782,340.63 from ¥1,694,478.60, marking a growth of 241.5%[65] Research and Development - Research and development expenses rose to ¥51,043,288.08, a 10.5% increase from ¥46,296,527.46 in the prior year[62]